Pharmaceutical Litigation Attorneys

Uloric (Febuxostat) is a prescription medication created to treat patients suffering from gout. Uloric was first put on the market in the United States in February of 2009.  The drug company that developed and sold Uloric is Takeda Pharmaceuticals. When Uloric was first put on the market, Takeda Pharmaceuticals did not warn doctors, or their patients, that Uloric could cause an increased risk of heart attacks, strokes or other cardiovascular problems, and that it could even cause death.

Our experienced team of medical product liability lawyers is now helping people who suffered a heart attack, stroke or death while taking Uloric medication to treat their gout.  These lawsuits are not against the doctors who prescribed Uloric.  These are product liability lawsuits against Takeda Pharmaceuticals.  The Takeda lawsuits are centered on a “failure to warn” claim because Takeda failed to warn the people taking Uloric of the increased risk of heart attacks and strokes shown to be caused by the medication.

Partner Christopher Schnieders has been named to the Plaintiffs' Executive Committee in In re: Uloric Products Liability Coordinated Pretrial Proceedings (Case No. 20 C 623) by United States District Court Judge Matthew Kennelly for the Northern District of Illinois.


Gout is a form of arthritis materializing as sudden, severe pain, redness, joint tenderness and swelling. Gout is often found in lower joints like the ankles, feet and toes, but it can also appear in the hands, wrists, and fingers.  Gout is caused by elevated uric acid levels in the blood and can be very painful and debilitating.


Uloric (Febuxostat) is a xanthine oxidase inhibitor prescribed for management of chronic hyperuricemia (increased Uric Acid levels in the blood) in adult patients with gout. Uloric originally was granted FDA approval on February 13, 2009.  When the Food and Drug Administration (FDA) approved Uloric in 2009, the FDA was concerned Uloric could be dangerous and could cause cardiovascular conditions, so it required that Takeda conduct a mandatory post-marketing cardiovascular safety study.

The results of the 6,000-patient safety study trial were published in the New England Journal of Medicine on March 29, 2018. The authors of the study found a statistically significant increased risk of cardiovascular death for users of Uloric compared to users of allopurinol.


If you or a loved one experienced a heart attack, stroke, kidney damage or if a loved one died while taking Uloric, then we will be seeking the following damages for you:

  • Past and future medical expenses that resulted from the injuries.
  • Funeral expenses if you lost a loved one.
  • Past and future pain and suffering (physical and mental) caused by the injuries.
  • Costs incurred related to the treatment and recovery process.
  • Past and future wage loss.
  • Past and future loss of earning capacity.
  • Past and future loss of the enjoyment of life.
  • Punitive damages, if appropriate.


If you, or a loved one, suffered a heart attack or stroke while taking Uloric, or if a loved one died of a heart attack or stroke while taking Uloric, please contact our legal team now for a free, no obligation consultation.
You may be entitled to substantial compensation for your injuries caused by Uloric.

This field is for validation purposes and should be left unchanged.

Contact Us:
Get a Free Case Evaluation Attorney Referral
Settlements In This Area
See All Settlements

Our Locations

Please Contact Us for an In-Person Appointment